我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

急性冠脉综合征TIMI 风险积分与脑钠尿肽及临床预后的关系(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2006年第4期
页码:
417-421
栏目:
临床研究
出版日期:
2006-08-25

文章信息/Info

Title:
Relation of TIMI risk score with plasma brain natriuretic peptide level and clinical prognosis in patients with acute coronary syndrome
作者:
丁嵩; 何奔; 卜军; 刘建平; 杜勇平; 宋玮; 金叔宣; 龚兴荣; 孙瑜; 沈珑
上海交通大学医学院附属仁济医院心内科，上海 200127
Author(s):
DING Song;  HE Ben;  BU Jun;  LIU Jian-ping;  DU Yongping;  SONG Wei;  JIN Shu-xuan;  GONG Xing-rong;  SUN Yu;  SHEN Long
Department of Cardiovascular Medicine, Renji Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200127, China
关键词:
急性冠脉综合征; TIMI 风险积分; 脑钠尿肽; 临床预后
Keywords:
acute coronary syndromes;  thrombolysis in myocardial infarction risk score;  brain natriuretic peptide;  clinical prognosis
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨TIMI风险积分对介入治疗后急性冠脉综合征（ACS）患者短期预后的预测作用及比较不同积分组血浆脑钠尿肽（BNP）水平。 方法 连续入选2004年11月至2005年4月因ST段抬高的心肌梗死（STEMI）在我院行经皮冠状动脉介入（PCI） 治疗者75例，因不稳定型心绞痛（UAP）/非ST段抬高的心肌梗死（NSTEMI）在我院行PCI 治疗者47例，入院时对入选患者进行心肌梗死溶栓试验（TIMI）风险积分。采用荧光免疫方法测定血浆BNP水平。 结果 在STEMI患者组，根据TIMI风险积分分为0~4分，5~9分，10~14分3组。随着TIMI风险积分升高，各组病死率呈明显递增趋势。在多变量的Logistic回归分析中，TIMI风险积分能够独立预测住院期间、1个月和3个月病死率及住院期间、1个月主要心血管不良事件（MACE）发生率(均P<0.01)。不同的TIMI风险积分各组间血浆BNP水平有显著性差异（P<0.01）。在多元回归分析中，TIMI风险积分分组不受年龄、性别、家族史、吸烟、高胆固醇血症、高血压、糖尿病等因素的影响, 而与血浆BNP水平呈独立正相关（r=0.52, P<0.01）。在UAP/NSTEMI患者组，根据TIMI风险积分分为0~2分，3~5分，5~7分3组。随着TIMI风险积分升高，各组病死率呈明显递增趋势。在多变量的Logistic回归分析中，TIMI风险积分能够独立预测3个月病死率及1个月和3个月 MACE发生率(均P<0.01)。各组间血浆BNP水平有显著性差异（P<0.01）。在多元回归分析中，TIMI风险积分分组经年龄、性别、高胆固醇血症因素校正后与血浆BNP水平呈正相关（r=0.41，P<0.01）。结论 TIMI 风险积分能够较好地对ACS患者进行危险分层，预测短期病死率和MACE发生率。ACS患者按TIMI 风险积分递增分组与血浆BNP水平呈正相关。TIMI 风险积分越高组血浆BNP水平越高。
Abstract:
AIM To evaluate the value of TIMI risk scores in estimating risk stratification in patients with acute coronary syndromes (ACS) and to determine the relationship between TIMI risk scores and plasma BNP level in ACS. METHODS The study population consisted of 123 consecutive patients with ACS who had undergone PCI (include 75 patients with STEMI and 47 patients with UAP/NSTMI). The TIMI risk score was calculated on admission and plasma BNP was measured by fluoroimmunoassay. RESULTS The TIMI risk scores for STEMI patients were calculated and were divided into 3 groups (TIMI scores 0 to 4, 5 to 9 and 10 to 14 ). The higher the TIMI risk scores on admission, the worse the prognosis. The TIMI risk score was an independent predictor of inhospital, 1month and 3month mortality as well as inhospital, 30 day incidence of MACE (P<0.01). The score could also predict 3 month (P<0.01) incidence of MACE if adjusted by hypercholesterolemia (P=0.0390). The plasma BNP level of these 3 groups was significantly different（P<0.01）. In the multivariate model, the TIMI risk score was positively correlated with the plasma BNP level（r=0.52, P<0.01）, independent of other known prognostic factors (included patient age, gender, family heredity, hypercholesterolemia, diabetes, hypertension and smoking). The TIMI risk scores for UAP/NSTEMI patients were calculated and they were divided into 3 groups (TIMI scores 0 to 2, 3 to 5and 6 to 7). The TIMI risk score was an independent predictor of 3month mortality and 1month and 3month incidence of MACE (P<0.01). The plasma BNP level of these 3 groups was significantly different（P<0.01）. In the multivariate model, the TIMI risk score was positively correlated with the plasma BNP level（r=0.41, P<0.01）. CONCLUSION This TIMI risk scoring system is a simple and practical tool at the bedside in quantitative risk evaluation and shortterm prognosis prediction in patients with ACS. The TIMI risk score is positively correlated with the plasma BNP level.

参考文献/References

［1］ Morrow DA, Antman EM,Charlesworth A,et al.TIMI risk score for STelevation myocardial infarction:A convenient,bedside,clinical score for risk assessment at presentation:An intravenous npA for treatment of infarcting myocardium early II trial substudy［J］.Circulation,2000,102(17):2031-2037.

［2］ Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/nonST elevation MI:A method for prognostication and therapeutic decision making［J］. JAMA， 2000,284(7):835-842.

［3］ Heeschen C,Hamm CW,Mitrovic V,et al. Nterminal proBtype natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes［J］. Circulation,2004,110(20):3206-3212.

［4］ Galvani M, Ottani F,Oltrona L,et al. Nterminal probrain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes［J］. Circulation,2004,110(2):128-134.

［5］ Morrow DA, Antman EM, Snapinn SM,et al. An integrated clinical approach to predicting the benefit of tirofiban in nonST elevation acute coronary syndromes. Application of the TIMI risk score for UA/NSTEMI in PRISMPLUS［J］. Eur Heart J, 2002,23(3):223–229.

［6］ Dao O, Krishnaswamy P,Kazanegra R,et al.Utility of Btype natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting［J］. J Am Coll Cardiol,2001,37(2):379-385.

［7］ Asada J, Tsuji H, Iwasaka T, et al. Usefulness of plasma brain natriuretic peptide levels in predicting dobutamineinduced myocardial ischemia［J］. Am J Cardiol, 2004,93(6):702-704.

［8］ Arakara N,Nakamura M,Aoki H,et al. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size［J］. Cardiology,,1994,85(5):334-340.

［9］ de Lemos JA,Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes［J］. Rev Cardiovasc Med,2003,4(suppl 4):S37-S46.

［10］Suzuki S,Yoshimura M,Nakayama M,et al. Plasma level of Btype natriuretic peptide as a prognostic market after acute myocardial infarction:a long term followup analyse［J］. Circulation,2004,110(11):1387-1391.

备注/Memo

备注/Memo:
收稿日期：2005-09-26.基金项目：上海市卫生局资助(No.044048) 通讯作者：何奔，主任医师，教授，主要从事冠心病介入治疗研究 Tel：（021）58752345-3477 Email: heben@medmail.com.cn 作者简介：丁嵩，住院医生，硕士 Tel:(021)58752345-3477 Email:dingsong1105@hatmail.com
更新日期/Last Update: